Topic

Articles

Effort aims to protect Americans from potentially harmful ophthalmic products.

FDA Warns Walgreens, Seven Others Against Promoting Unapproved Eye Products 

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

AstraZeneca Joins Legal Battle Against IRA

Delay to allow agency to consider other ways of solving the issue, filing says. 

Report: FTC Temporarily Suspends Challenge to $27.8B Amgen-Horizon Merger 

Meg Rivers is the former managing editor of 

In this exclusive Q&A, Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, shares her perspective on the biggest drug pricing challenges today, current efforts to lower drug pricing, and the Inflation Reduction Act. 

Drug Pricing from a Legal Perspective & IRA Predictions

Lisa Henderson is the former group editorial director of 

While ESG is still in the early stages for pharma, many companies are moving forward with a need for compliance.

Checklist compliance clipboard | Image Credit: © Andrii - stock.adobe.com

PCC 2023: ESG, New Turf for Compliance

is head of external affairs and ESG at Organon. In this role, she focuses on guiding and shaping how the company interacts with key stakeholders and the environment.

Examining efforts to boost women representation on company boards.

Pharma Governance and the Quest for Gender Equity

The validity of ESG-driven investment and reporting in healthcare.

Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?

Dr. Pamela Walker is Global Head of Health at Kin + Carta Advise.

A prime opportunity for pharma to raise its strategic game in ESG.

ESG: Applying  Lessons From Consumer Market 

U.S. patent law will have to adapt to the use of AI in the life sciences industry.

As Pharma Continues to Adapt to AI, the POSA Standard will Need to Equally Adapt

How principles of both can help companies navigate future storms.